Schizophrenia 3 - Clinical (2)

[P249] Evaluation of neuromelanin in patients with treatment-resistant schizophrenia

*Ryosuke Tarumi^1,2, Shiori Honda¹, Takahide Etani^3,4, Saki Homma³, Yuka Kaneko⁵, Karin Matsushita¹, Sotarou Moriyama¹, Yui Tobari¹, Fumihiko Ueno^1,6, Guillermo Horga⁷, Clifford Cassidy⁸, Sakiko Tsugawa¹, Hiroyuki Uchida^1,6, Ariel GraffGuerrero⁶, Yoshihiro Noda^1,6, Shinichiro Nakajima^1,6 (1. Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan, 2. Seikei-Kai Komagino Hospital, Japan, 3. Graduate School of Media and Governance, Keio University, Kanagawa, Japan, 4. School of Medicine, College of Medical, Pharmaceutical, and Health, Kanazawa University, Kanazawa, Japan, 5. Faculty of Policy Manegement, Keio University, Kanagawa, Japan, 6. Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 7. Department of Psychiatry, Columbia University, New York, NY, US, 8. Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada)

Keywords:schizophrenia, neuromelanin, treatment-resistant schizophrenia